Jean-Christophe Renondin

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Novagali Pharma SA specializes in research, development and marketing of ophthalmic drugs. Their product pipeline includes products at various stages of development, which address diseases encountered at the three different segment levels of the eye which are surface, anterior and posterior segments. Some of these diseases are dry eye, allergy, glaucoma and retinopathies. Their formulations are based on their technology platforms Novasorb and Eyeject, which optimize bioavailability of drugs as well as safety and comfort for the patient. The company was founded on August 8, 2000 and is headquartered in Evry, France.

Xytis, Inc. was engaged in the development of central nervous system. The company was founded by Werner Tschollar in January 2006 and was headquartered in Irvine, CA.

Innovation Capital SASU (Innovation Capital) is the international venture capital subsidiary of CDC Capital Investissement SAS, itself a wholly-owned subsidiary of State-owned CDC Caisse des Dépôts et Consignations in France. Established in 1996 as CDC Entreprises Innovation, the firm was formerly known as CDC Innovation SASU. They changed their name to Innovation Capital SASU in 2012. Located in Paris with representative offices in California and in Switzerland, the firm manages venture capital and innovation mutual funds (FCPRs and FCPIs). Their venture capital funds are sponsored by CDC Capital Investissement, and the innovation funds are generally co-invested with the venture capital funds. The firm's mandate includes public interest missions.

Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France.